ASCO 2020 data on treatment with nivolumab plus brentuximab vedotin in standard-risk young patients with R/R classical Hodgkin lymphoma as reported by Clinical Care Options (CCO)
From ASCO 2020, new data confirm significant efficacy and tolerability of acalabrutinib in CLL and other B-cell malignancies, reported by Clinical Care Options (CCO)
Latest data from a phase I study of AMG 330 in patients with acute myeloid leukemia from ASCO 2020, as reported by Clinical Care Options (CCO)
Updated data from phase III BELLINI study of venetoclax plus bortezomib/dexamethasone in R/R myeloma from ASCO 2020 as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.